Radiation Induced Cystitis Treated With Hyperbaric Oxygen - A Randomized Controlled Trial (RICH-ART)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01659723 |
|
Recruitment Status :
Completed
First Posted : August 8, 2012
Last Update Posted : June 26, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
The primary objective of this study is to assess the relief of symptoms after Hyperbaric Oxygen Therapy (HBOT) in patients with late radiation cystitis by having Expanded Prostate cancer Index Composite (EPIC)symptom estimation scale as primary variable.
Study hypothesis:
- HBOT can reduce or reverse the change or otherwise limit the damage of the bladder function and/or structure, which arose as a result of radiation therapy of cancer in the pelvic region organs.
- The effects of HBOT are associated with relief of symptoms that, at least in part, is related to the reduction of the extent of the radiation damage.
- Vascular density increases, fibrosis prevalence and inflammatory activity are reduced as a sign of an improved function of the mucosa.
- Treatment results of HBOT remains, in whole or in part, during the follow-up (residual effect)
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Cystitis, Radio Induced | Drug: Hyperbaric Oxygen | Phase 2 Phase 3 |
Radiotherapy is commonly used in the management of malignant diseases. Despite a continuous improvement of the technique, with improved efficacy and tolerance, adverse effects are still rather common. The urinary bladder and rectum are the major organs most commonly affected by radiotherapy to the pelvis area.
One of the most significant causes of the symptoms of radio therapy is inflammation and degeneration of blood vessels in the radiated tissue. Hyperbaric oxygen therapy involves administration of oxygen at greater than normal atmospheric pressures. A well-documented effect of HBOT is the stimulation of angiogenesis. HBOT is an established treatment for degeneration of blood vessels in the jaw bone as a result of radiotherapy and several publications have shown good efficacy also when soft tissue is affected.
If the method of treatment with HBOT means a reduction of the radiotherapy side effect it is thus an obvious importance for the individual patient. There is also significant potential savings for the healthcare and society.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 75 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Single (Outcomes Assessor) |
| Primary Purpose: | Treatment |
| Official Title: | Radiation Induced Cystitis Treated With Hyperbaric Oxygen - A Randomized Controlled Trial |
| Study Start Date : | August 2012 |
| Actual Primary Completion Date : | August 9, 2018 |
| Actual Study Completion Date : | August 9, 2018 |
| Arm | Intervention/treatment |
|---|---|
|
Active Comparator: A - Immediate start
Start of treatment within 6 weeks of inclusion in the study. 100% oxygen at 240-250 kPa will be delivered to the patents for 80-90 minutes while sitting or lying in a hyperbaric oxygen chamber. Patients will receive treatment once every day, except week-ends, for 40 days.
|
Drug: Hyperbaric Oxygen
100% oxygen at 240-250 kPa will be delivered to the patents for 80-90 minutes while sitting or lying in a hyperbaric oxygen chamber. Patients will receive treatment once every day, except week-ends, for 40 days. |
|
No Intervention: B - delayed start
Delayed start: Start of treatment not before 6 months of inclusion in the study. No intervention is given during the initial period.
|
- EPIC (Expanded Prostate cancer Index Composite) [ Time Frame: At inclusion, 6 months after inclusion (i.e. post treatment for group A and pre treatment for group B) and for long-term follow-up as specified under "description" ]
EPIC was developed to measure health-related quality of life among men with prostate cancer (22) modified to enhance sensitivity to therapy effects. It comprises four summary domains; urinary, bowel, sexual and hormonal.
The primary objective of this study is to assess the relief of symptoms after HBOT in patients with late radiation cystitis by having EPIC symptom estimation scale as primary variable, comparing results between group A (post treatment) and group B (pre treatment).
All patients (Group A and B) will complete EPIC and SF-36 in a post-study long-term follow-up. This is done yearly for 5 years (18, 30, 42, 54 and 66 months post inclusion).
- Microscopic assessment [ Time Frame: At inclusion and 6 months after inclusion (i.e. post treatment for group A and pre treatment for group B) ]To investigate the mucosa with respect to functionality by assessment of inflammation activity, quantification of fibrosis, vascular density and the presence of stems cells having histological analysis from biopsies as variable. Comparison will be made between group A (post treatment) and group B (pre treatment)
- RTOG (Radiation Toxicity Grade by Radiation Therapy Oncology Group) [ Time Frame: At inclusion and 6 months after inclusion (i.e. post treatment for group A and pre treatment for group B) ]
RTOG is an internationally well established research group in the oncology field. They have developed organ specific scales for quantification of both acute and late symptoms after radiation. The scale range is from 0 to 5, where 0 is used for normal function and findings and 5 for death directly related to injuries post radiation. Both subjective and objective findings are used when setting the score.
Comparison will be made between Group A (post treatment) and Group B (pre treatment)
- SF-36 (Short Form Health Survey 36) [ Time Frame: At inclusion, 6 months after inclusion (i.e. post treatment for group A and pre treatment for group B) and for long-term follow-up as specified under "description" ]
SF-36 is a self-administered questionnaire and contains 36 items which measure eight dimensions and assess health-related quality of life. Comparing results between Group A (post treatment) and Group B (pre treatment).
All patients (Group A and B) will complete EPIC and SF-36 in a post-study long-term follow-up. This is done yearly for 5 years (18, 30, 42, 54 and 66 months post inclusion).
- Adverse events [ Time Frame: Every day during HBOT (8 weeks). ]Adverse events (AE) are recorded during HBOT and Serious adverse events (SAE) until visit 4.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 80 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Provision of informed consent prior to any study specific procedures
- Female or male aged 18-80 years
- Intended curative radiation of the pelvic region as a treatment for cancer
- End of radiation therapy more than 6 months ago
- Radiation cystitis with Urological EPIC < 80
- Radiation cystitis is the most probable cause for the patient's symptoms
Exclusion Criteria:
- Patients with major and ongoing bleedings from the bladder (requiring more than 0.5L blood-transfusion within the last four weeks)
- Refractory incontinence requiring catheter or surgical intervention
- Urine bladder capacity < 100ml
- Fistula in the urine bladder
- Contraindications for HBOT according to the local centres routines
- Pregnancy
- Mechanical ventilator support
- Unable to follow and understand simple commands
- Not oriented to person, place and time
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01659723
| Denmark | |
| Rigshospitalet Copenhagen | |
| Copenhagen, Denmark | |
| Finland | |
| Turku Hospital | |
| Turku, Finland | |
| Norway | |
| Haukeland Universitetssykehus | |
| Bergen, Norway | |
| Sweden | |
| Shalgrenska University Hospial | |
| Gothenburg, Sweden | |
| Karolinska University Hospital | |
| Stockholm, Sweden | |
| Principal Investigator: | Nicklas Oscarsson, MD | Sahlgrenska, Gothenburg University |
Documents provided by Göteborg University:
| Responsible Party: | Göteborg University |
| ClinicalTrials.gov Identifier: | NCT01659723 |
| Other Study ID Numbers: |
RICH-ART 2012-001381-15 2012-001381-15 ( EudraCT Number ) |
| First Posted: | August 8, 2012 Key Record Dates |
| Last Update Posted: | June 26, 2019 |
| Last Verified: | June 2019 |
|
Radio therapy STRI Urinary bladder Hyperbaric Oxygen |
|
Cystitis Urinary Bladder Diseases Urologic Diseases Female Urogenital Diseases |
Female Urogenital Diseases and Pregnancy Complications Urogenital Diseases Male Urogenital Diseases |